Xiaoxing Qiu1, Lori Sokoll2, Paul Yip3, Debra J Elliott2, Renu Dua2, Phaedre Mohr2, Xiao Yan Wang3, Megan Spencer3, Priscilla Swanson4, George J Dawson4, John Hackett4. 1. Infectious Disease Research, Abbott, Diagnostics, Abbott Park, IL, United States. Electronic address: xiaoxing.qiu@abbott.com. 2. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, United States. 3. Department of Laboratory Medicine and Pathobiology, University of Toronto and University Health Network, Toronto, ON, Canada. 4. Infectious Disease Research, Abbott, Diagnostics, Abbott Park, IL, United States.
Abstract
BACKGROUND: HIV Ag/Ab combination assays are recommended by CDC for routine screening and several HIV Ag/Ab combination tests are now FDA-approved. Maintaining high specificity and consistent sensitivity across diverse HIV strains is critical for these assays to accurately detect HIV infection and expedite delivery of patient results. OBJECTIVES: To evaluate performance of three FDA-approved HIV tests: ARCHITECT HIV Combo (Abbott), ADVIA Centaur HIV Combo (Siemens) and BioPlex HIV Ag-Ab (Bio-Rad). STUDY DESIGN: Sensitivity and specificity were evaluated using an extensive panel of 28 HIV infected human specimens and 17 cultured virus isolates representing multiple genotypes, 6 seroconversion panels, 4 human samples with acute infection, WHO p24 standard and 4020 clinical specimens. RESULTS: The p24 limit of detection (LOD) for the WHO standard was 0.19IU/ml, 0.70IU/ml, and 1.77IU/ml in BioPlex, ARCHITECT, and Centaur respectively. The distribution of LODs across 15 HIV-1 isolates was substantially narrower in ARCHITECT (5-33pg/ml) than in BioPlex (11-198pg/ml) and Centaur (6-384pg/ml). All assays detected antibodies to the majority of HIV-1 and HIV-2 variants. However, reduced sensitivity was observed for Centaur in detection of antibodies to HIV-1 group M (CRF02_AG), O and N variants. BioPlex and ARCHITECT showed better seroconversion sensitivity than Centaur, detecting one bleed (3-7 days) earlier in 4 (BioPlex) and 3 (ARCHITECT) of 6 seroconversion panels. ARCHITECT demonstrated the highest specificity (99.90-100%) compared to BioPlex (99.80%) and Centaur (99.42%). CONCLUSIONS: The overall performance of ARCHITECT and BioPlex was superior to Centaur, especially for detection of acute HIV infection.
BACKGROUND: HIV Ag/Ab combination assays are recommended by CDC for routine screening and several HIV Ag/Ab combination tests are now FDA-approved. Maintaining high specificity and consistent sensitivity across diverse HIV strains is critical for these assays to accurately detect HIV infection and expedite delivery of patient results. OBJECTIVES: To evaluate performance of three FDA-approved HIV tests: ARCHITECT HIV Combo (Abbott), ADVIA Centaur HIV Combo (Siemens) and BioPlex HIV Ag-Ab (Bio-Rad). STUDY DESIGN: Sensitivity and specificity were evaluated using an extensive panel of 28 HIV infectedhuman specimens and 17 cultured virus isolates representing multiple genotypes, 6 seroconversion panels, 4 human samples with acute infection, WHO p24 standard and 4020 clinical specimens. RESULTS: The p24 limit of detection (LOD) for the WHO standard was 0.19IU/ml, 0.70IU/ml, and 1.77IU/ml in BioPlex, ARCHITECT, and Centaur respectively. The distribution of LODs across 15 HIV-1 isolates was substantially narrower in ARCHITECT (5-33pg/ml) than in BioPlex (11-198pg/ml) and Centaur (6-384pg/ml). All assays detected antibodies to the majority of HIV-1 and HIV-2 variants. However, reduced sensitivity was observed for Centaur in detection of antibodies to HIV-1 group M (CRF02_AG), O and N variants. BioPlex and ARCHITECT showed better seroconversion sensitivity than Centaur, detecting one bleed (3-7 days) earlier in 4 (BioPlex) and 3 (ARCHITECT) of 6 seroconversion panels. ARCHITECT demonstrated the highest specificity (99.90-100%) compared to BioPlex (99.80%) and Centaur (99.42%). CONCLUSIONS: The overall performance of ARCHITECT and BioPlex was superior to Centaur, especially for detection of acute HIV infection.
Authors: Mars Stone; John Bainbridge; Ana M Sanchez; Sheila M Keating; Andrea Pappas; Wes Rountree; Chris Todd; Sonia Bakkour; Mark Manak; Sheila A Peel; Robert W Coombs; Eric M Ramos; M Kathleen Shriver; Paul Contestable; Sangeetha Vijaysri Nair; David H Wilson; Martin Stengelin; Gary Murphy; Indira Hewlett; Thomas N Denny; Michael P Busch Journal: J Clin Microbiol Date: 2018-07-26 Impact factor: 5.948
Authors: Mark M Manak; Linda L Jagodzinski; Ashley Shutt; Jennifer A Malia; Mike Leos; Jason Ouellette; Siriwat Akapirat; Donn L Colby; Nittaya Phanuphak; Leigh Anne Eller; Merlin L Robb; Mark de Souza; Jintanat Ananworanich; Sheila A Peel Journal: J Clin Microbiol Date: 2019-09-24 Impact factor: 5.948
Authors: Susan H Eshleman; Estelle Piwowar-Manning; Mariya V Sivay; Barbara Debevec; Stephanie Veater; Laura McKinstry; Linda-Gail Bekker; Sharon Mannheimer; Robert M Grant; Margaret A Chesney; Thomas J Coates; Beryl A Koblin; Jessica M Fogel Journal: J Clin Virol Date: 2018-01-11 Impact factor: 3.168
Authors: Mary A Rodgers; Ana S Vallari; Julie Yamaguchi; Vera Holzmayer; Barbara Harris; Coumba Toure-Kane; Souleymane Mboup; Samar Badreddine; Carole McArthur; Nicaise Ndembi; Dora Mbanya; Lazare Kaptue; Gavin Cloherty Journal: AIDS Res Hum Retroviruses Date: 2018-02-13 Impact factor: 2.205
Authors: Denise L Uettwiller-Geiger; Marvin Lessig; Jie An; Tara Barsch; Susan Smith; Sharan Walker; Alexander Riedel; Yi Hao; Amin A Mohammad Journal: Am J Clin Pathol Date: 2019-03-01 Impact factor: 2.493
Authors: Junpeng Zhao; Xiaoting Lv; Le Chang; Huimin Ji; Barbara J Harris; Lu Zhang; Xinyi Jiang; Fei Guo; John Hackett; Peng Yin; Gavin A Cloherty; Mary A Rodgers; Lunan Wang Journal: Sci Rep Date: 2020-05-05 Impact factor: 4.379